9月17日，维康药业（维权）盘中下跌2.02%，截至10:30，报23.32元/股，成交6744.97万元，换手率 1.97%，总市值33.77亿元。 资料显示，浙江维康药业股份有限公司位于浙江省丽水经济开发区遂松路2号，成立日期2000年3月31 日，上市日期2020年8月24日，公司主营业务涉及现代中药及西药的研发、生产和销售。主营业务收入 构成为：中西成药97.16%，其他(补充)2.84%。 维康药业所属申万行业为：医药生物-中药Ⅱ-中药Ⅲ。所属概念板块包括：肝炎治疗、抗流感、医药电 商、中药、小盘等。 截至6月30日，维康药业股东户数9892.00，较上期减少12.06%；人均流通股14569股，较上期增加 13.71%。2025年1月-6月，维康药业实现营业收入1.15亿元，同比减少61.42%；归母净利润-6421.97万 元，同比减少552.50%。 分红方面，维康药业A股上市后累计派现1.79亿元。近三年，累计派现5540.00万元。 责任编辑：小浪快报 资金流向方面，主力资金净流出289.42万元，大单买入795.25万元，占比11.79%，卖出1084.67万元，占 比16.08%。 维 ...

Core Viewpoint - 康希诺's stock price has shown volatility with a year-to-date increase of 33.84%, but recent trading indicates a slight decline in the short term [1][2]. Financial Performance - As of June 30, 康希诺 reported a revenue of 3.82 billion yuan for the first half of 2025, reflecting a year-on-year growth of 26.00% [2]. - The company experienced a net profit loss of 1348.54 million yuan, which is an improvement of 94.02% compared to the previous period [2]. Stock Market Activity - On September 17, 康希诺's stock price decreased by 2.07%, trading at 81.71 yuan per share with a total market capitalization of 202.19 billion yuan [1]. - The stock saw a net outflow of 616.01 million yuan in principal funds, with significant selling pressure from large orders [1]. Shareholder Information - As of June 30, 康希诺 had 17,500 shareholders, a decrease of 1.92% from the previous period [2]. - The average number of circulating shares per shareholder remained at 0 [2]. Dividend Information - 康希诺 has distributed a total of 1.98 billion yuan in dividends since its A-share listing, with no dividends paid in the last three years [3].

9月16日，普洛药业盘中下跌2.04%，截至10:56，报16.31元/股，成交1.10亿元，换手率0.58%，总市值 188.94亿元。 资金流向方面，主力资金净流出799.49万元，特大单买入180.51万元，占比1.64%，卖出111.14万元，占 比1.01%；大单买入1845.14万元，占比16.80%，卖出2714.00万元，占比24.71%。 普洛药业今年以来股价涨2.53%，近5个交易日涨3.03%，近20日涨0.06%，近60日涨16.58%。 今年以来普洛药业已经1次登上龙虎榜，最近一次登上龙虎榜为3月11日，当日龙虎榜净买入-1.45亿 元；买入总计8564.04万元 ，占总成交额比13.36%；卖出总计2.31亿元 ，占总成交额比36.04%。 普洛药业所属申万行业为：医药生物-化学制药-原料药。所属概念板块包括：抗流感、多肽药、禽流感 药物、原料药、宠物经济等。 截至6月30日，普洛药业股东户数5.14万，较上期减少0.52%；人均流通股22508股，较上期减少0.41%。 2025年1月-6月，普洛药业实现营业收入54.44亿元，同比减少15.31%；归母净利润5.63亿元，同比减 ...

9月16日，振东制药盘中下跌2.13%，截至10:39，报7.35元/股，成交1.13亿元，换手率1.51%，总市值 73.89亿元。 资料显示，山西振东制药股份有限公司位于山西省长治市上党区光明南路振东科技园，成立日期1995年 11月15日，上市日期2011年1月7日，公司主营业务涉及肿瘤、毛发、消化、泌尿、心脑等仿制药、创新 药的研发、生产、销售,以及种子种苗抚育、种植、加工、仓储、饮片于一体的中药材全产业链。主营 业务收入构成为：中药54.82%，化药43.10%，其他1.98%，销售材料0.10%，研发收入0.00%。 资金流向方面，主力资金净流出2859.85万元，特大单买入0.00元，占比0.00%，卖出555.02万元，占比 4.93%；大单买入1634.09万元，占比14.51%，卖出3938.91万元，占比34.98%。 振东制药所属申万行业为：医药生物-中药Ⅱ-中药Ⅲ。所属概念板块包括：抗流感、维生素、医药电 商、肝炎治疗、幽门螺杆概念等。 截至6月30日，振东制药股东户数4.61万，较上期减少5.04%；人均流通股21777股，较上期增加5.31%。 2025年1月-6月，振东制药实现 ...

9月16日，一品红盘中下跌2.06%，截至10:13，报60.93元/股，成交1.24亿元，换手率0.48%，总市值 275.22亿元。 资金流向方面，主力资金净流出1741.82万元，特大单买入259.43万元，占比2.10%，卖出703.22万元， 占比5.68%；大单买入1980.41万元，占比16.00%，卖出3278.45万元，占比26.48%。 一品红今年以来股价涨257.15%，近5个交易日跌11.13%，近20日跌14.83%，近60日涨19.56%。 一品红所属申万行业为：医药生物-化学制药-化学制剂。所属概念板块包括：抗流感、医药电商、肝炎 治疗、中药、猴痘概念等。 截至8月31日，一品红股东户数2.14万，较上期增加0.49%；人均流通股19553股，较上期减少0.49%。 2025年1月-6月，一品红实现营业收入5.84亿元，同比减少36.02%；归母净利润-7354.22万元，同比减少 258.30%。 分红方面，一品红A股上市后累计派现3.35亿元。近三年，累计派现1.51亿元。 机构持仓方面，截止2025年6月30日，一品红十大流通股东中，易方达医疗保健行业混合A（110023） ...

Core Points - The stock price of Zhenbao Island decreased by 2.05% on September 15, trading at 11.96 CNY per share with a total market capitalization of 11.254 billion CNY [1] - The company has seen a year-to-date stock price increase of 4.45%, with a recent 5-day increase of 0.93%, a 20-day decrease of 3.31%, and a 60-day increase of 7.46% [2] - Zhenbao Island's main business involves the research, production, and sales of high-end traditional Chinese medicine, with 84.82% of revenue coming from product sales [2] Financial Performance - For the first half of 2025, Zhenbao Island reported a revenue of 714 million CNY, a year-on-year decrease of 57.05%, and a net profit attributable to shareholders of -78.29 million CNY, a decrease of 119.90% [2] - The company has distributed a total of 1.302 billion CNY in dividends since its A-share listing, with 356 million CNY distributed over the past three years [3] Shareholder Information - As of July 18, Zhenbao Island had 21,500 shareholders, an increase of 2.34% from the previous period, with an average of 43,744 circulating shares per shareholder, a decrease of 2.29% [2]

Core Viewpoint - Kangyuan Pharmaceutical's stock price has shown volatility, with a year-to-date increase of 19.60% but a recent decline of 4.68% over the past five trading days and 7.71% over the past twenty days [2] Group 1: Stock Performance - As of September 12, Kangyuan Pharmaceutical's stock price was 16.29 CNY per share, with a market capitalization of 9.223 billion CNY [1] - The stock experienced a trading volume of 2.41 billion CNY and a turnover rate of 2.57% [1] - The company has seen a net outflow of 24.27 million CNY in principal funds, with large orders showing a buy of 56.96 million CNY and a sell of 80.70 million CNY [1] Group 2: Financial Performance - For the first half of 2025, Kangyuan Pharmaceutical reported a revenue of 1.642 billion CNY, a year-on-year decrease of 27.36%, and a net profit attributable to shareholders of 142 million CNY, down 46.36% year-on-year [2] - The company has distributed a total of 949.8 million CNY in dividends since its A-share listing, with 345 million CNY distributed over the last three years [3] Group 3: Shareholder Information - As of June 30, 2025, the number of shareholders for Kangyuan Pharmaceutical was 34,600, a decrease of 15.24% from the previous period [2] - The average circulating shares per person increased by 17.98% to 16,371 shares [2] - Hong Kong Central Clearing Limited is the fifth-largest circulating shareholder, holding 14.0379 million shares, a decrease of 9.89 million shares from the previous period [3]

Core Viewpoint - The stock price of Zhenbaodao has shown a mixed performance in recent months, with a year-to-date increase of 7.69% and a notable drop in revenue and net profit for the first half of 2025 [2][3]. Company Overview - Zhenbaodao Pharmaceutical Co., Ltd. is located in Harbin, Heilongjiang Province, and was established on October 28, 1996. It was listed on April 24, 2015. The company specializes in the research, production, and sales of high-end traditional Chinese medicine [2]. - The main business revenue composition includes: 84.82% from the sale of proprietary Chinese medicine, 7.13% from purchased medicinal materials, 5.11% from purchased pharmaceuticals, 2.51% from other sources, 0.35% from rental income, and 0.07% from interest income [2]. Stock Performance - As of September 12, Zhenbaodao's stock price increased by 2.07%, reaching 12.33 CNY per share, with a total market capitalization of 11.602 billion CNY. The trading volume was 90.0689 million CNY, with a turnover rate of 0.79% [1]. - Year-to-date, the stock price has increased by 7.69%, with a 4.14% rise over the last five trading days, a slight decline of 0.16% over the last 20 days, and an increase of 11.18% over the last 60 days [2]. Financial Performance - For the first half of 2025, Zhenbaodao reported an operating income of 714 million CNY, a significant decrease of 57.05% year-on-year. The net profit attributable to the parent company was -78.2899 million CNY, reflecting a year-on-year decrease of 119.90% [2]. - Since its A-share listing, Zhenbaodao has distributed a total of 1.302 billion CNY in dividends, with 356 million CNY distributed over the past three years [3]. Shareholder Information - As of July 18, the number of shareholders for Zhenbaodao was 21,500, an increase of 2.34% from the previous period. The average circulating shares per person decreased by 2.29% to 43,744 shares [2].

Group 1 - The core viewpoint of the news is that CanSino's stock has experienced fluctuations, with a current price of 83.06 CNY per share and a market capitalization of 20.55 billion CNY, reflecting a year-to-date increase of 36.05% [1] - As of June 30, CanSino had 17,500 shareholders, a decrease of 1.92% from the previous period, with an average of 0 circulating shares per shareholder [2] - For the first half of 2025, CanSino reported a revenue of 382 million CNY, representing a year-on-year growth of 26%, while the net profit attributable to shareholders was -13.49 million CNY, showing a significant increase in losses of 94.02% [2] Group 2 - CanSino's main business involves the research, production, and commercialization of innovative vaccines, with vaccine sales accounting for 97.84% of total revenue [1] - The company has cumulatively distributed 198 million CNY in dividends since its A-share listing, with no dividends distributed in the past three years [3] - CanSino operates within the pharmaceutical and biotechnology industry, specifically in the vaccine sector, and is associated with concepts such as monkeypox, anti-influenza, and biopharmaceuticals [1]

Company Overview - Nanjing Pharmaceutical Co., Ltd. is located in Guangzhou, Guangdong Province, and was established on December 27, 2006. The company was listed on March 26, 2020. Its main business focuses on the research, production, and sales of antiviral drugs for influenza and other infectious diseases, as well as treatments for major diseases such as cardiovascular diseases and diabetes. The revenue composition is entirely from chemical drug formulations, accounting for 100% [1]. Stock Performance - As of September 12, Nanjing Pharmaceutical's stock price decreased by 2.07%, trading at 12.75 CNY per share, with a total market capitalization of 3.499 billion CNY. The stock has increased by 94.95% year-to-date, but has seen a decline of 7.47% in the last five trading days and 5.42% in the last 20 days. Over the past 60 days, the stock has risen by 77.33% [1]. - The company has appeared on the "Dragon and Tiger List" six times this year, with the most recent appearance on August 27, where it recorded a net buy of 104 million CNY, accounting for 30.60% of total trading volume [1]. Financial Performance - For the first half of 2025, Nanjing Pharmaceutical reported a revenue of 61.8463 million CNY, a year-on-year decrease of 71.28%. The net profit attributable to the parent company was -40.0023 million CNY, reflecting a significant decline of 493.23% compared to the previous period [2]. - The company has cumulatively distributed 40.74 million CNY in dividends since its A-share listing, with no dividends distributed in the last three years [3]. Shareholder Information - As of June 30, 2025, the number of shareholders increased by 7.02% to 9,464, while the average number of tradable shares per person decreased by 6.56% to 28,994 shares [2]. - Among the top ten circulating shareholders, Dazheng Jingheng Mixed A (090019) holds 2.9738 million shares, with no change in the number of shares held compared to the previous period [3].